AMAT
36
5
CAG
30
4
COST
58
-2
LB
34
8
DAL
80
-4
ALLE
37
5
FMC
31
5
JNJ
41
2
COF
55
-3
SYK
64
-4
FLS
73
-2
SO
55
-2
EQT
59
2
DHI
48
3
AXP
66
2
EW
37
-2
IBM
54
4
WAT
47
5
UA
45
-3
ORLY
53
-3
AMAT
36
5
CAG
30
4
COST
58
-2
LB
34
8
DAL
80
-4
ALLE
37
5
FMC
31
5
JNJ
41
2
COF
55
-3
SYK
64
-4
FLS
73
-2
SO
55
-2
EQT
59
2
DHI
48
3
AXP
66
2
EW
37
-2
IBM
54
4
WAT
47
5
UA
45
-3
ORLY
53
-3
Financhill
Back

Addex Therapeutics 10K Form

Sell
15

ADXN
Addex Therapeutics

Last Price:
7.58
Seasonality Move:
36.23%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ADXN News And Ratings

See the #1 stock for the next 7 days that we like better than ADXN

ADXN Financial Statistics

Sales & Book Value

Annual Sales: $1.8M
Cash Flow: $-2.96M
Price / Cash Flow: 0
Annual Sales: $13.17
Price / Book: 0.56

Profitability

EPS (TTM): -1.64250
Net Income (TTM): $4.52M
Gross Margin: $2.55M
Return on Equity: 90.28%
Return on Assets: 54.9%

Addex Therapeutics Earnings Forecast

Key Addex Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 8 years for ADXN is 91.70%.
  • The Selling, General & Administrative Expenses for ADXN have been equal to 446.69% of Gross Profit Margin.
  • The Research & Development expenses have been 170.40% of Revenue.
  • The Interest Expense is -0.20% of Operating Income.
  • The Net Earning history of ADXN is -654.47% of Total Revenues.
  • Per Share Earnings over the last 18 years have been positive in 13 years.

Addex Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ADXN
Website: addextherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.97
Quick Ratio: 4.67

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ADXN Technical Analysis vs Fundamental Analysis

Sell
15
Addex Therapeutics (ADXN) is a Sell

Is Addex Therapeutics a Buy or a Sell?